老年急性髓系白血病中继发性AML样基因突变在ELN中危组的附加预后价值:ALFA-1200研究结果
这项前瞻性ALFA-1200试验纳入509例年龄≥60岁(中位68岁)接受强化化疗的急性髓系白血病(AML)患者,对471份样本进行多基因分析。48%的样本携带继发性AML(sAML)样基因突变,这些突变与更短的无事件生存相关(总体HR 1.46,95%CI 1.19-1.79,P<.001;ELN-2017中危亚组HR 1.52,95%CI 1.01-2.28,P=.044)。将携带sAML样突变的中危患者与高危患者合并为高危组后,移植仅延长高危组缓解后总生存,不延长标危组。
要点
- 老年AML强化化疗患者中48%样本携带sAML样基因突变。
- sAML样突变与更短无事件生存相关,总体HR 1.46(95%CI 1.19-1.79,P<.001)。
- ELN-2017中危亚组中sAML样突变HR 1.52(95%CI 1.01-2.28,P=.044)。
核心结论
- sAML样基因突变的常规分析可能改善老年AML高危患者的定义,并更好识别可从首次缓解后异基因移植中明确获益的那一半老年患者。
研究设计与样本
- 前瞻性ALFA-1200试验于2012年至2016年纳入509例年龄≥60岁(中位68岁)接受强化化疗的AML患者,471份样本进行多基因分析。
主要发现
- 48%的分析样本携带sAML样基因突变(ASXL1、SRSF2、STAG2、BCOR、U2AF1、EZH2、SF3B1、ZRSR2中任一突变)。
- sAML样突变与更短无事件生存相关:总体HR 1.46(95%CI 1.19-1.79,P<.001)。
- ELN-2017中危亚组(按定义排除ASXL1突变病例)中sAML样突变HR 1.52(95%CI 1.01-2.28,P=.044)。
- 将携带sAML样突变的中危患者与高危患者合并为高危组,其他中危患者与标危患者合并为标准风险组,高危/标准风险患者比为1.00。
- 按此二分类风险评估,移植仅延长高危AML患者缓解后总生存,不延长标准风险AML患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled in the intensive Acute Leukemia French Association (ALFA)-1200 trial between 2012 and 2016, and 471 patient samples were submitted to multigene analysis. Mutations in any of 8 genes frequently altered in myelodysplastic syndromes (MDS), including ASXL1, SRSF2, STAG2, BCOR, U2AF1, EZH2, SF3B1, and ZRSR2, defined a secondary AML (sAML)-like disease, as reported. Of the samples analyzed, 48% included sAML-like gene mutations. These mutations were associated with a shorter event-free survival, both overall (hazard ratio, 1.46; 95% confidence interval, 1.19-1.79; P < .001) and within the European LeukemiaNet (ELN)-2017 intermediate-risk subgroup (hazard ratio, 1.52; 95% confidence interval, 1.01-2.28; P = .044), which excludes ASXL1-mutated cases by definition. We therefore included patients with intermediate-risk AML carrying sAML-like mutations in a single high-risk patients group together with adverse-risk patients with AML, whereas other intermediate-risk patients were included in a standard-risk group together with favorable-risk patients (high-risk/standard-risk patient ratio, 1.00). Using this 2-class risk assessment, we observed that transplantation prolonged overall survival from remission in patients with high-risk AML only, not in patients with standard-risk AML. Routine analysis of sAML-like gene mutations may thus improve the definition of high-risk older patients with AML, and better identify the half of older patients who clearly derive survival benefit from allogeneic transplantation in first remission. This trial was registered at www.clinicaltrials.gov as #NCT01966497.
引用
- Gardin C, Pautas C, Fournier E, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020. PMID: 32380535. doi:10.1182/bloodadvances.2019001349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。